RxDoctor Payments Data

Naeem Haider, MD

Nephrology · Jacksonville, FLNPI 1811924210

Payments from drug & device makers

$1,775in general payments, 2019–2025

Across 46 payments — averaging $38.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$583
  • Fresenius USA Marketing, Inc.$279
  • Intuitive Surgical$172
  • Abbott$137
  • Travere Therapeutics, Inc.$135
  • GSK$125
  • plus $343 from 7 others

What the payments were for

  • Food & beverage$1,51986%
  • Education$25614%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,775 in reported general payments places this provider in the 50th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$561,422
Medicare patients
561
Services billed
5,498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide223$464,386
AuryxiaFerric Citrate121$224,357
FarxigaDapagliflozin Propanediol97$120,738
Sevelamer Carbonate217$42,781
Lanthanum Carbonate56$38,440
EliquisApixaban36$23,817
EntrestoSacubitril/Valsartan12$23,396
FosrenolLanthanum Carbonate18$22,770
JanuviaSitagliptin Phosphate13$18,318
LokelmaSodium Zirconium Cyclosilicate12$16,237
Febuxostat102$11,983
Cinacalcet Hcl31$6,576
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen132$5,570
Torsemide140$5,052
Midodrine Hcl27$3,727

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$279$464,386223 claims
Akebia Therapeutics IncAuryxia$56$224,357121 claims
AstraZenecaFarxiga, Lokelma$583$136,975109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 756 nephrology providers in Florida.

Other nephrology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →